These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33918409)

  • 1. Evaluation of DNA-Launched Virus-Like Particle Vaccines in an Immune Competent Mouse Model of Chikungunya Virus Infection.
    Rayner JO; Kim JH; Roberts RW; Wood RR; Fouty B; Solodushko V
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33918409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
    Thompson D; Metz SW; Abad C; Beaty S; Warfield K
    Vaccine; 2022 May; 40(22):3009-3017. PubMed ID: 35459557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation.
    Seymour RL; Adams AP; Leal G; Alcorn MD; Weaver SC
    PLoS Negl Trop Dis; 2015; 9(6):e0003800. PubMed ID: 26115459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models.
    Langsjoen RM; Haller SL; Roy CJ; Vinet-Oliphant H; Bergren NA; Erasmus JH; Livengood JA; Powell TD; Weaver SC; Rossi SL
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate.
    Plante KS; Rossi SL; Bergren NA; Seymour RL; Weaver SC
    PLoS Negl Trop Dis; 2015; 9(9):e0004007. PubMed ID: 26340754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Progress in Vaccine Development Against Chikungunya Virus.
    Gao S; Song S; Zhang L
    Front Microbiol; 2019; 10():2881. PubMed ID: 31921059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation sequencing of DNA-launched Chikungunya vaccine virus.
    Hidajat R; Nickols B; Forrester N; Tretyakova I; Weaver S; Pushko P
    Virology; 2016 Mar; 490():83-90. PubMed ID: 26855330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
    JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
    López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
    J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
    Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
    Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
    Basu R; Zhai L; Rosso B; Tumban E
    Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
    Metz SW; Pijlman GP
    Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.
    Akhrymuk I; Lukash T; Frolov I; Frolova EI
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.